Skip to content

Immunome IMNM Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Operating margin-5,947.9%-2,719pp-3,228.8%-809pp-2,419.9%-636pp-1,784.1%+210pp-1,994.3%+1,388pp
Net margin-5,593.8%-2,534pp-3,060%-759pp-2,301.3%-614pp-1,687.1%+188pp-1,875.2%+1,365pp
Returns
Return on equity-50.1%+1.9pp-52.1%+40.9pp-93%-11.8pp-81.2%-12.0pp-69.2%+125pp
Efficiency
Asset turnover0.0×0.0×0.0×0.0×0.0×
Liquidity
Current ratio21.7×+7.0×14.7×+5.8×8.9×-3.2×12.1×+1.6×10.5×+6.4×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Per Share
Book value per share$5.20-28.3%$7.26+142%$3.00-3.0%$3.09-20.0%$3.87+25.2%
Valuation
Market capitalization$2.47B+4.4%$2.37B+133%$1.02B+31.3%$776.15M+32.6%$585.18M-11.7%
Price / sales616.2×+275×341.4×+236×105.3×+43.7×61.7×+8.2×53.5×-19.8×
Price / book4.2×+0.5×3.7×-0.1×3.9×+1.0×2.9×+1.0×1.9×-1.8×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Immunome's ratios come from?
Every ratio is computed from Immunome's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.